BioGend Therapeutics Co (ROCO:6733) Beta: 0.5851 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6733 BioGend Therapeutics Co Ltd ROCO:6733
73 GF Score
Price NT$25.35
GF Value NT$70.22
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is BioGend Therapeutics Co Beta?

BioGend Therapeutics Co ROCO:6733 -2.50% 73 Beta is 0.5851 as of Jul. 14, 2026. GuruFocus rates ROCO:6733 with a GF Score™ of 73/100 and a GF Value™ of NT$70.22 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-14), BioGend Therapeutics Co's Beta is 0.5851.


BioGend Therapeutics Co  (ROCO:6733) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


BioGend Therapeutics Co Beta Related Terms


BioGend Therapeutics Co Beta Historical Data

* Premium members only.

The historical data trend for BioGend Therapeutics Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGend Therapeutics Co Beta Chart

BioGend Therapeutics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.82 0.58 0.59 0.00

BioGend Therapeutics Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.00 0.00 0.00 0.00

ROCO:6733 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, BioGend Therapeutics Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGend Therapeutics Co Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's Beta distribution charts can be found below:

* The bar in red indicates where BioGend Therapeutics Co's Beta falls into.


ROCO:6733
73GF Score
BioGend Therapeutics Co Ltd ROCO:6733
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGend Therapeutics Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.5851 mean?
BioGend Therapeutics Co (ROCO:6733) has a Beta of 0.5851 as of Jul. 14, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BioGend Therapeutics Co and its competitors.
Is BioGend Therapeutics Co's Beta too high?
BioGend Therapeutics Co's current Beta is 0.5851. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Beta compare to VRTX and REGN?
BioGend Therapeutics Co's Beta of 0.5851 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BioGend Therapeutics Co and its competitors. BioGend Therapeutics Co's current Beta is 0.5851. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$70.22, compared to a current price of NT$25.35 — trading 63.9% below its estimated fair value. The current Beta is 0.5851. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Beta is 0.5851 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?

Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued. The current stock price of NT$25.35 is trading 63.9% below its estimated GF Value™ of NT$70.22. GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.

Key valuation signals for ROCO:6733:

  • Beta: 0.5851
  • GF Value™: NT$70.22 vs. price of NT$25.35 (63.9% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioGend Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 115
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score

Get the complete analysis for ROCO:6733

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$25.35
Price
NT$70.22
GF Value